content

As Vaccine Firms Prep For A Busy Season, Influenza May Hit

Flu season is just around the horizon as the summer draws to a close and fall looms. Influenza still poses a threat, and leading...

Gene Therapy By Bluebird Bio Costing $2.8M Given Nod By FDA

Gene therapy for blood disorders developed by Bluebird Bio has already left the nest in the US. Zynteglo, sometimes known as betibeglogene autotemcel (beti-cel), was...

Achema 2022: Syntegon presents new Service Agreements

At this yearโ€™s Achema, Syntegon will present redesigned Service Agreement packages for effective asset and maintenance management at fixed costs. The varied agreements help...

ADCs Built On Starpharma Delivery Tech To Be Tested By Merck

As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will...

After Roe, Bayer Engages Lobbyists For Contraception Access

While a large portion of the biopharma industry prepares for a battle over medication prices, Bayer is getting ready for a different lobbying push...

Trodelvy Wins A Battle Against Breast Cancer With Gilead

Gilead staked money on Trodelvy providing a life-extension benefit when it failed to show promise in halting tumour development in HR-positive HER2-negative breast cancer....

Study Uncovers And Exploits Flaws In Some High-Risk Cancers

A team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director of the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read